About us

Company Overview

Arrien Pharmaceuticals is a technology driven biopharmaceutical company focused on discovery and development of innovative and effective drug candidates for the treatment of human cancers. The company currently has three drug candidates for oncology and two other programs in development for non-oncology indications.

ARN-6039 Phase 1 clinical trials completed agent initially licensed to Boston Pharmaceuticals in 2017 further licensed to Xenter, Inc.

ARN-3261 is a SIK2 inhibitor in development, competed its IND enabling studies, and Licensed to Greenfire Bio. Clinical Phase 1a/1b trial initiated in Q2 2021.

Mission & Values

We believe that our foremost responsibility lies with the millions of patients around the world and our focus is on the discovery and development of new drugs to treat patients where the current therapeutics are inadequate.